Legacy Wealth Management LLC MS Has $3.63 Million Position in IQVIA Holdings Inc. $IQV

Legacy Wealth Management LLC MS lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,095 shares of the medical research company’s stock after selling 3,144 shares during the period. IQVIA makes up approximately 1.1% of Legacy Wealth Management LLC MS’s investment portfolio, making the stock its 16th largest position. Legacy Wealth Management LLC MS’s holdings in IQVIA were worth $3,627,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the company. Everpar Advisors LLC lifted its holdings in shares of IQVIA by 4.6% during the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock worth $221,000 after buying an additional 62 shares in the last quarter. Private Trust Co. NA raised its position in shares of IQVIA by 12.5% in the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after buying an additional 67 shares in the last quarter. E Fund Management Co. Ltd. boosted its stake in shares of IQVIA by 3.7% in the second quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after buying an additional 74 shares during the period. Harbor Capital Advisors Inc. increased its stake in IQVIA by 2.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 2,795 shares of the medical research company’s stock worth $531,000 after acquiring an additional 78 shares during the period. Finally, Penserra Capital Management LLC raised its holdings in IQVIA by 10.3% in the 2nd quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock valued at $151,000 after acquiring an additional 90 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Down 0.5%

IQV opened at $243.18 on Friday. The business’s 50-day simple moving average is $223.85 and its 200-day simple moving average is $199.58. The company has a market cap of $41.41 billion, a P/E ratio of 33.36, a PEG ratio of 2.49 and a beta of 1.36. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $246.71. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter in the prior year, the business posted $2.84 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on IQV shares. Evercore ISI raised their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Hsbc Global Res upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. JPMorgan Chase & Co. upped their price objective on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Morgan Stanley lifted their target price on IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Finally, Barclays set a $230.00 target price on IQVIA in a research note on Monday, December 15th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $246.63.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.